Notch1 inhibitors such as γ-secretase are potential therapeutic agents for treatment of tumor, Alzheimer’s disease and cardiovascular diseases [6,7,9,10]. This evidence concerns the gene NOTCH1 and early-onset autosomal dominant Alzheimer disease.